IPP Bureau
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
By IPP Bureau - April 08, 2026
The trial also demonstrated significant improvements across multiple secondary endpoints
Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity
By IPP Bureau - April 08, 2026
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Aurobindo Pharma wins USFDA approval for generic Xigduo XR
By IPP Bureau - April 08, 2026
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals
By IPP Bureau - April 08, 2026
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
EU nod to Rezurock for chronic GVHD in adults & teens
By IPP Bureau - April 08, 2026
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Thailand and GHIT Fund join forces to tackle infectious diseases
By IPP Bureau - April 08, 2026
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Alkem enters daily wellness space with launch of 'A to Z Daily' multivitamin
By IPP Bureau - April 08, 2026
New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet
Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity
By IPP Bureau - April 08, 2026
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Merck expands Bengaluru plant to strengthen global filtration supply chain
By IPP Bureau - April 08, 2026
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer
By IPP Bureau - April 07, 2026
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
World Health Day: Late diagnosis, rising lifestyle diseases put young India at risk
By IPP Bureau - April 07, 2026
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Fischer Medical converts warrants into equity, infuses Rs 10.53 crore
By IPP Bureau - April 07, 2026
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Aurobindo Pharma’s CuraTeQ achieves Phase 3 success for Omalizumab biosimilar
By IPP Bureau - April 07, 2026
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
HRV Pharma, Shodhana join hands to build next-gen API pipeline for global markets
By IPP Bureau - April 07, 2026
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
MedGenome’s RNA-based NGS study sharpens sarcoma diagnosis, alters treatment in 25% cases
By IPP Bureau - April 07, 2026
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
